{"id":70184,"date":"2024-06-11T07:27:12","date_gmt":"2024-06-11T07:27:12","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/06\/11\/bengaluru-company-global-initiative-to-take-new-compound-against-superbugs-to-patients-times-of-india\/"},"modified":"2024-06-11T07:27:12","modified_gmt":"2024-06-11T07:27:12","slug":"bengaluru-company-global-initiative-to-take-new-compound-against-superbugs-to-patients-times-of-india","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/06\/11\/bengaluru-company-global-initiative-to-take-new-compound-against-superbugs-to-patients-times-of-india\/","title":{"rendered":"Bengaluru company, global initiative to take new compound against superbugs to patients &#8211; Times of India"},"content":{"rendered":"<div style=\"text-align:center\"><img loading=\"lazy\" decoding=\"async\" width=\"1280\" height=\"720\" src=\"https:\/\/i0.wp.com\/static.toiimg.com\/photo\/msid-110896676,imgsize-1188301.cms?resize=1280,720&amp;ssl=1\" class=\"attachment-post-thumbnail size-post-thumbnail wp-post-image\" alt=\"Bengaluru company, global initiative to take new compound against superbugs to patients &#8211; Times of India\" title=\"Bengaluru company, global initiative to take new compound against superbugs to patients &#8211; Times of India\" \/><\/div>\n<div>BENGALURU: The Global <!-- -->Antibiotic<!-- --> Research &amp; Development Partnership (<!-- -->GARDP<!-- -->) and Bengaluru-based <!-- -->Bugworks<!-- --> Research Inc are collaborating to co-develop a promising new antibiotic compound \u2014 \u201cBWC0977\u201d \u2014 with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. <br \/>As per the agreement, GARDP will provide up to $20 million to Bugworks in technical and financial support for the pharmaceutical and clinical co-development of <!-- -->BWC0977<!-- -->.<!-- -->In return, Bugworks has granted GARDP manufacturing and commercialisation rights for the compound in 146 nations, almost all of which are low-or middle-income countries (LMICs).<br \/>\u201c&#8230;BWC0977 has shown potent activity against two \u2018critical priority\u2019 <!-- -->superbugs<!-- --> (drug resistant pathogens) identified by the WHO \u2013 carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae \u2013 which are increasingly untreatable and accounted for over 20% of antimicrobial resistance (AMR)-associated deaths in 2019 according to the global research on AMR study,\u201d the release read. <br \/>Manica Balasegaram, GARDP\u2019s executive director said \u201cBWC0977\u201d stands out for its novelty and potential to address unmet public health needs against priority pathogens where few treatments exist.<br \/>Anand Anandkumar, co-founder and CEO, Bugworks, which incubated at the Centre for Cellular and Molecular Platforms (C-CAMP) in Bengaluru, said: \u201cAn overarching goal of this partnership is to enable access to this compound simultaneously in Western countries and in LMICs with high AMR burden.<br \/>The GARDP-Bugworks collaboration builds on more than $12.4 million in prior funding from CARB-X to advance BWC0977 through early-stage research and initial clinical testing.<br \/>The release, issued by C-CAMP, reads: \u201cThe development of BWC0977 reflects the bolstering of the global health ecosystem to respond to the AMR crisis. CARB-X has provided critical support for the pre-clinical development and first-in-human (phase 1) clinical study of this compound. GARDP will now collaborate with Bugworks to further develop BWC0977 and, upon approval, enable global access.\u201d<br \/>CARB-X R&amp;D chief Erin Duffy, while stating that CARB-X was proud of its financial and non-financial support for the Bugworks programme, said now that this compound has been primed for advanced development, they look forward to GARDP\u2019s support in bringing this potential novel, broad-spectrum antibiotic to patients.<\/div>\n<p><script>!(function(f, b, e, v, n, t, s) {\n    function loadFBEvents(isFBCampaignActive) {\n      if (!isFBCampaignActive) {\n        return;\n      }\n      (function(f, b, e, v, n, t, s) {\n        if (f.fbq) return;\n        n = f.fbq = function() {\n          n.callMethod ? n.callMethod(...arguments) : n.queue.push(arguments);\n        };\n        if (!f._fbq) f._fbq = n;\n        n.push = n;\n        n.loaded = !0;\n        n.version = '2.0';\n        n.queue = [];\n        t = b.createElement(e);\n        t.async = !0;\n        t.defer = !0;\n        t.src = v;\n        s = b.getElementsByTagName(e)[0];\n        s.parentNode.insertBefore(t, s);\n      })(f, b, e, 'https:\/\/connect.facebook.net\/en_US\/fbevents.js', n, t, s);\n      fbq('init', '593671331875494');\n      fbq('track', 'PageView');\n    };\n    function loadGtagEvents(isGoogleCampaignActive) {\n      if (!isGoogleCampaignActive) {\n        return;\n      }\n      var id = document.getElementById('toi-plus-google-campaign');\n      if (id) {\n        return;\n      }\n      (function(f, b, e, v, n, t, s) {\n        t = b.createElement(e);\n        t.async = !0;\n        t.defer = !0;\n        t.src = v;\n        t.id = 'toi-plus-google-campaign';\n        s = b.getElementsByTagName(e)[0];\n        s.parentNode.insertBefore(t, s);\n      })(f, b, e, 'https:\/\/www.googletagmanager.com\/gtag\/js?id=AW-877820074', n, t, s);\n    };\n    function loadSurvicateJs(allowedSurvicateSections = []){\n      const section =  window.location.pathname.split('\/')[1]\n      const isHomePageAllowed = window.location.pathname === '\/' && allowedSurvicateSections.includes('homepage')\n      if(allowedSurvicateSections.includes(section) || isHomePageAllowed){\n        (function(w) {\n          var s = document.createElement('script');\n          s.src=\"https:\/\/survey.survicate.com\/workspaces\/0be6ae9845d14a7c8ff08a7a00bd9b21\/web_surveys.js\";\n          s.async = true;\n          var e = document.getElementsByTagName('script')[0];\n          e.parentNode.insertBefore(s, e);\n        })(window);\n      }\n    }\n    window.TimesApps = window.TimesApps || {};\n    var TimesApps = window.TimesApps;\n    TimesApps.toiPlusEvents = function(config) {\n      var isConfigAvailable = \"toiplus_site_settings\" in f && \"isFBCampaignActive\" in f.toiplus_site_settings && \"isGoogleCampaignActive\" in f.toiplus_site_settings;\n      var isPrimeUser = window.isPrime;\n      if (isConfigAvailable && !isPrimeUser) {\n        loadGtagEvents(f.toiplus_site_settings.isGoogleCampaignActive);\n        loadFBEvents(f.toiplus_site_settings.isFBCampaignActive);\n        loadSurvicateJs(f.toiplus_site_settings.allowedSurvicateSections);\n      } else {\n        var JarvisUrl=\"https:\/\/jarvis.indiatimes.com\/v1\/feeds\/toi_plus\/site_settings\/643526e21443833f0c454615?db_env=published\";\n        window.getFromClient(JarvisUrl, function(config){\n          if (config) {\n            loadGtagEvents(config?.isGoogleCampaignActive);\n            loadFBEvents(config?.isFBCampaignActive);\n            loadSurvicateJs(config?.allowedSurvicateSections);\n          }\n        })\n      }\n    };\n  })(\n    window,\n    document,\n    'script',\n  );<\/script><br \/>\n<br \/><br \/>\n<br \/><a href=\"https:\/\/timesofindia.indiatimes.com\/business\/india-business\/bengaluru-company-global-initiative-to-take-new-compound-against-superbugs-to-patients\/articleshow\/110894596.cms\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BENGALURU: The Global Antibiotic Research &amp; Development Partnership (GARDP) and Bengaluru-based Bugworks Research Inc are collaborating to co-develop a promising new antibiotic compound \u2014 \u201cBWC0977\u201d \u2014 with broad-spectrum antibiotic activity against multidrug-resistant bacteria that cause life-threatening infections. As per the agreement, GARDP will provide up to $20 million to Bugworks in technical and financial support [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":70185,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","fifu_image_url":"https:\/\/static.toiimg.com\/photo\/msid-110896676,imgsize-1188301.cms","fifu_image_alt":"","footnotes":""},"categories":[604],"tags":[10338,3849,65267,289,65266,1126,36647,65265,377,273,21736,9164,40100,272],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/70184"}],"collection":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/comments?post=70184"}],"version-history":[{"count":1,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/70184\/revisions"}],"predecessor-version":[{"id":70186,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/70184\/revisions\/70186"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media\/70185"}],"wp:attachment":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media?parent=70184"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/categories?post=70184"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/tags?post=70184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}